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ABSTRACT
OBJECTIVE: To assess whether the incidence of hospital infection by a resistant microorganism 
decreased after the implementation of the restrictive measure of the National Health Surveillance 
Agency for the commercialization of antimicrobials. 
METHODS: A historical cohort study of medical records of adult patients admitted to a general 
and public hospital from May 2010 to July 2011. A cohort was formed with patients admitted 
in the period before the restrictive measure for the commercialization of antimicrobials 
(Phase I) and a second cohort was formed with patients admitted after the implementation of 
the restrictive measure (Phase II). 
RESULTS: The instantaneous risk of hospital infection by a resistant microorganism 
was estimated at seven by 1,000 people-time (95%CI 0.006–0.008) in Phase I, and four by 
1,000 people-time (95%CI 0.003–0.005) in Phase II of the study. The differences between the 
survival curves in the different phases of the study and stratified by age group were also 
significant (p < 0.05).
CONCLUSIONS: The results suggest that the implementation of the restrictive measure of 
the commercialization of antimicrobials by the National Health Surveillance Agency reduced 
the incidence of hospital infection by a resistant microorganism.
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INTRODUCTION
Bacterial resistance to antimicrobials (ATM) poses a serious threat to global public 
health. Despite its multifactorial genesis, one of the main factors that triggers it is the 
unnecessary and abusive use of ATM, a fact extensively described in the international 
and national literature1–4.
Resistance can decrease the effectiveness of ATM, requiring the administration of second line 
drugs, which are usually more toxic and costly, causing damage to the patient and increasing 
the hospitalization time and expenses for the individual and for the health system5,6.
Specific characteristics of developing countries favor the occurrence of microbial 
resistance in these places, such as low hygiene conditions, poor living conditions, poor 
quality of medications and access to the parallel market of ATM7. An increase in the 
consumption of ATM in emerging countries is identified, with Brazil being among the 
five countries with the highest indices between 2000 and 20108. Studies on microbial 
resistance published in the country so far present incipient data9, but show expressive 
increase in the resistance of these organisms and, consequently, increased morbidity and 
mortality and the cost of infections10,11.
Microbial resistance can be developed by selective pressure resulting from exposure to 
ATM and from the exchange of genetic material among several species of microorganisms. 
In this context, exposure to ATM is a fundamental factor in the selection of resistant 
species. Among the strategies to minimize the development of resistance, the reduction of 
the prescription of ATM and the implementation of strategies that stimulate rational use 
at Community level or in hospitals have deserved prominence5,6,12. The optimizationa of 
the use of ATM is among the five objectives of the Global Action Plan of the World Health 
Organization (WHO) to control microbial resistance13, in order to reduce the supply and 
overprescription of antibiotics for human and veterinary use, as well as to strengthen the 
regulation of its use worldwide. In Brazil, up to 2010 the ATM could be acquired only with 
the presentation of the prescription, limiting the supervision and favoring self-medication. 
The collegiate board of the National Health Surveillance Agency (ANVISA), through RDC 
44, published on October 26, 2010, in its Art. 2nd determined that prescribed antibiotics 
can only be dispensed with special control prescription, aiming to restrict the free access 
to these drugs and minimize the occurrence of microbial resistance14.
Inadequate use of ATM at Community level contributes to the selection of resistant strains 
and dissemination of resistance genes15. Since studies indicate that its use in hospitals 
affects the community microbial resistance and vice versa4,16,17, it is relevant to evaluate the 
impact of the implementation of restrictive measures for the marketing of these medicines 
in both environments.
In the literature, scientific publications indicate the influence of the restrictive measure in 
the consumption of ATM in Brazil18,19, but no publications were identified on the impact 
of this measure on the reduction of microbial resistance in the hospital environment. 
Given this context that hospital infections raise health expenditures and cause harm to 
patients, our study aimed to compare the occurrence of microbial resistance in a hospital 
environment before and after the implementation of the restrictive measure of ANVISA 
for the commercialization of ATM in Brazil.
METHODS
Study Design, Location and Population
This is a historical cohort study including adult patients admitted to the Hospital Risoleta 
Tolentino Neves (HRTN) in the period from May 2010 to July 2011. HRTN is a general public 
a Antimicrobial optimization 
consists of prescription through 
effective, fast and inexpensive 
diagnostic techniques, in 
addition to the prescription and 
regulation based on evidence 
and effective regulation and 
control techniques13.
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emergency hospital that has about 330 beds, being a reference for the northern region of 
Belo Horizonte and neighboring municipalities. Approximately 10,000 patients are attended 
each month, most are attended in the emergency room and about 13.0% of the patients are 
hospitalized in the same institution.
We included patients over 18 years of age, for whom culture exams were requested due to 
suspected hospital infection or routine procedures to identify bacterial colonization. Patients 
with diagnosis of bacterial infection at admission or up to 72 hours after hospitalization, 
women hospitalized for childbirth and puerperium, and patients transferred from another 
hospital or with length of stay of less than 72 hours were excluded.
This study consisted of two cohorts: The first included patients admitted to the HTRN from 
May to October 2010, period before the restrictive measure for the commercialization of 
ATM (Phase I), and the second was formed by patients admitted between February and 
July 2011, after the implementation of the measure of ANVISA (Phase II). The option for 
this period aimed to obtain symmetrical time intervals that minimized the interference 
of non-controllable factors such as turnover of professionals, shortage of the supply 
of medications and inf luence of non-standardization of procedures to conduct the 
examinations of the institution. The team responsible for controlling infections associated 
with health care at the institution and the clinical body did not undergo alterations during 
the study period, but a change was recorded in the laboratory that performed the exams 
in the HRTN in the second semester of 2011 (period after data collection). No shortage of 
supply of medications occurred during the study periods.
Definition of Study Variables
The outcome of interest was infection or hospital colonization by a microorganism resistant 
to ATM, evidenced by positive results of in vitro culture of microorganisms and result of the 
sensitivity test to Antimicrobial agents (in vitro antibiogram), interpreted as “resistant” in 
patients with hospitalization stay exceeding 72 hours20. In this study, microbial resistance 
was defined as the antibiotic resistance from a clinical point of view, considering a higher 
probability of therapeutic failure when an infection by a given microorganism is treated 
with a class of antibiotics customarily used in clinical practice21, identified by resistance 
results in the antibiogram.
The predictor variables were the phases of the study (before and after the implementation 
of the restrictive measure), age (adults < 60 years old and older adults ≥ 60 years), sex 
and risk profile of the patients. In relation to the last variable, the hospital under study 
has a management process in which patients are classified according to the following 
clinical risk profiles: critically ill patients (assisted in the polytrauma care sector and 
in the intensive care center), patients in the medical clinic (usually hospitalized for 
worsening chronic health problems), surgical patients (requiring surgical intervention), 
and maternal-infant profile (maternity and pediatrics). As the patients treated in the 
maternity and pediatrics sectors did not present inclusion criteria, the following risk 
profiles were considered in the study: critically ill, in the medical clinic and surgical 
patients. The clinical profile was considered a proxy variable of clinical severity or of 
performing invasive procedures of greater impact.
We also identified the total number of culture exams requested by the patient, the resistant 
microorganisms and the resistance profile. The microorganisms were classified as producers 
of extended spectrum β-lactamases (ESBL) when the isolate was a producer of extended 
spectrum β-lactamase. Those classified as Klebsiella pneumoniae carbapenemase (KPC) were 
those whose strains were carbapenemase-producing, identified by the positive Hodge Test22. 
Also according to the recommendations of the institutional protocol, the growth of atypical 
microorganisms and fungi in blood culture was counted as resistance when considering 
the severity of the clinical consequences of these situations. In case of the result “microbial 
growth in mixed culture,” the examination was repeated.
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The procedures of culture collection in the HRTN occurred in case of clinical suspicion 
of infection or through the culture of axillary and anophanous swab, whose institutional 
protocol recommended weekly collection for patients with hospitalization time exceeding 
15 days, even without signs or symptoms of infection.
Data Collection and Analysis
The information on bacterial resistance and predictor variables was collected from 
secondary data, through the review of the patient’s electronic record and the generation 
of computerized reports.
Regarding the identification of microbial resistance, a computerized report of all the culture 
exams performed for the patients under study was generated, then the results were checked. 
In specific cases, the information was complemented with records of the hospital infection 
control committee on the resistance profile in the institution.
Descriptive analysis of the variables was performed for the study population, with 
distribution of absolute and relative frequencies and measures of central tendency and 
variability. Survival curves estimated by the Kaplan-Meier method were used to compare 
the time until the occurrence of at least one hospital infection record by a resistant 
microorganism in the two phases of the study. The same method was used to compare 
differences between the study phases stratified by age group. The free time of the outcome 
was calculated between the date of hospital admission and the occurrence of the first episode 
of the outcome of interest, censored by the occurrence of death or by hospital discharge in 
both phases of the study. The Cox proportional hazards model was used to estimate the 
incidence density ratio (hazard ratio) for microbial resistance infection (MRI) according to 
the predictor variables. For all analyses, a 0.05% significance level was adopted. All analyses 
were conducted using the Stata statistical software version 13.0.
Ethical Considerations
The project was approved by the Human Research Ethics Committee of the Federal 
University of Viçosa (Opinion 176/2012).
RESULTS
During the study period, 5,178 hospitalizations for 4,786 patients in Phase I and 4,618 
hospitalizations for 4,261 patients in Phase II were analyzed. Approximately 53.0% of 
the patients were men (52.1% and 53.0% in Phases I and II, respectively), with a mean 
age of 49.2 (SD = 20.8) years in Phase I and 49.7 (SD = 21.2) years in Phase II (p > 0.05 for 
sex and age).
From the total of patients monitored in Phase I, culture exams were requested for 922 
patients (19.3%), and 8,149 exams were performed, with an average of 8.8 exams per patient. 
In Phase II, exams were requested for 684 (14.8%) patients, and a total of 3,404 exams were 
performed, corresponding to an average of 5.0 exams per patient.
Of the total tests performed, 1,803 and 1,130 isolates were identified in Phases I and II, 
respectively. Approximately 1,109 (62%) isolates in Phase I showed resistance, while in Phase 
II, resistance was identified in 381 (34%) isolates. In Table 1, resistant microorganisms are 
described by phase.
The incidence density of hospital infection by a resistant microorganism (in number of 
cases per hospitalization/day) was significantly higher in Phase I (7 for 1,000 people-time, 
95%CI 0.006–0.008) compared with Phase II (4 for 1,000 people-time, 95%CI 0.003–0.005). 
We observed that the free time of infection by bacterial resistance of 75% of the study 
population was 27 days in Phase I and 60 days in Phase II (Figure 1).
5Restrictive measure and antimicrobial use Costa JM et al.
http://dx.doi.org/10.11606/s1518-8787.2019053000879
Table 1. Resistance profile of microorganisms by study phase.
Resistant microorganism
Phase I 
(n)
Phase II 
(n)
Resistance profile
Acinetobacter baumannii 308 124
Imipenem or Meropenem or Ceftazidime or 
Ceftriaxone or Cefotaxime or Cefepime
Achromobacter sp. 1 0
Imipenem or Meropenem or Ceftazidime or 
Ceftriaxone or Cefotaxime or Cefepime
Alcaligenes faecalis 2 0 ATYPICAL*
Candida sp.* 8 9 ATYPICAL*
Citrobacter sp. 1 4
Imipenem or Meropenem or Ceftazidime or 
Ceftriaxone or Cefotaxime or Cefepime
Carbapenemase-producing 
Enterobacter aerogenes 
1 0 Meropenem and imipenem
Enterobacter sp. 54 16
Imipenem or Meropenem or Ceftazidime or 
Ceftriaxone or Cefotaxime or Cefepime
Enterococcus sp. 138 21 Vancomycin
Escherichia coli 20 25
Ceftazidime or Ceftriaxone or Cefotaxime or Ciprofloxacin 
or Levofloxacin or Gatifloxacin or Cefepime
ESBL-producing Escherichia coli 11 1 Beta-lactams
Geotrichum candidum 1 0 ATYPICAL*
Haemophilus sp. 1 0 ATYPICAL*
Klebsiella sp. 35 12
Imipenem or Meropenem or Ceftazidime or 
Ceftriaxone or Cefotaxime or Cefepime
ESBL-producing Klebsiella 
pneumoniae
19 0 Beta-lactams
Carbapenemase-producing 
Klebsiella pneumoniae
5 2 Beta-lactams
Morganella morganii 5 4
Imipenem or Meropenem or Ceftazidime or 
Ceftriaxone or Cefotaxime or Cefepime
Proteus mirabilis 23 53
Imipenem or Meropenem or Ceftazidime or 
Ceftriaxone or Cefotaxime or Cefepime
ESBL-producin Proteus mirabilis 0 3 Beta-lactams
Providencia stuartii 2 3
Imipenem or Meropenem or Ceftazidime or 
Ceftriaxone or Cefotaxime or Cefepime
Pseudomonas aeruginosa 133 46
Ciprofloxacin or Levofloxacin or Imipenem or 
Meropenem or Ceftazidime or Piperacillin or Cefepime
Salmonella group 1 0 ATYPICAL*
Serratia sp. 11 3
Imipenem or Meropenem or Ceftazidime or 
Ceftriaxone or Cefotaxime or Cefepime
Sphingomonas paucimobilis* 2 0 Sulfamethoxazole + Trimethoprim
Staphylococcus aureus 228 10 Oxacillin
Staphylococcus sp. 21 17 Oxacillin
Staphylococcus epidermidis 33 19 Oxacillin
Staphylococcus haemolyticus 23 6 Oxacillin
Coagulase-negative staphylococcus 8 3 Oxacillin
Stenotrophomonas maltophilia* 5 0 Sulfamethoxazole + Trimethoprim
Streptococcus agalactiae (beta-
hemolytic) of group B
3 0
Penicillin or Ceftazidime or Ceftriaxone or Cefotaxime 
or Cefepime
Streptococcus pneumoniae 1 0
Penicillin or Ceftazidime or Ceftriaxone or Cefotaxime 
or Cefepime
Streptococcus pyogenes 2 0
Penicillin or Ceftazidime or Ceftriaxone or Cefotaxime 
or Cefepime
Non-pneumococcus Streptococcus 
sp. (alpha-hemolytic)
3 0
Penicillin or Ceftazidime or Ceftriaxone or Cefotaxime 
or Cefepime
Total resistants 1,109 381
ESBL: Extended spectrum beta-lactamase
* Microorganisms considered atypical because they are not incorporated into the hospital microbiota. According 
to the institutional protocol, they are counted as resistant, considering the severity of the clinical consequences of 
infections and the need to implement surveillance strategies to prevent future infections by these pathogens. As to 
fungi, they were counted as resistant in cases of blood infections.
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In the stratified analysis by age group, differences were found between the instantaneous 
risk in the study phases for both groups (Log-rank, p < 0.05). In adults, the instantaneous risk 
was five for 1,000 people-time (95%CI 0.004–0.006) in Phase I and three for 1,000 people-time 
(95%CI 0.002–0.004) in Phase II. In older adults (60 years or more), in Phase I it was 0.010 
(95%CI 0.008–0.011) and in Phase II it was 0.006 (95%CI 0.005–0.007). The free time of MRI 
in 75% of the adults was 36 days in Phase I, while in Phase II the outcome was observed in 
less than 25% of them. The free time of MRI in 75% of the older adults was 25 and 48 days 
in Phases I and II, respectively. In both age groups, the differences in the free time of MRI 
between the phases were statistically significant (Figure 2). The free time of MRI was lower 
in Phase I compared with Phase II for those in the medical clinic, surgical and critically ill 
profiles (Log-rank, p < 0.05) (Figure 3).
Figure 1. Survival curve free from microbial resistance for hospitalized patients. Belo Horizonte, MG, 
2010–2011.
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Figure 2. Survival curve free from microbial resistance for (A) adult patients and (B) hospitalized older adults. Belo Horizonte, MG, 2010–2011.
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Figure 3. Survival curve free from microbial resistance for (A) critically ill, (B) in the medical clinic and 
(C) surgical patients. Belo Horizonte, MG, 2010–2011.
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In the multivariate analysis, we found that age, study phase and risk profile remained 
independently associated with the risk of MRI. Controlling by age and risk profile, the 
risk of MRI in Phase II was approximately 50% lower than the same risk in Phase I 
(Table 2).
DISCUSSION
This study shows the contributions of the restrictive measure in reducing the incidence 
density of nosocomial infections in a population of older patients in a general hospital in 
Brazil, even after adjusting for age. These findings are important to the scientific literature, 
considering that, although this measure was adopted in 2010, little is known about its impact 
on microbial resistance in the hospital environment.
Few Brazilian studies have been conducted in order to identify the contributions of the 
restrictive measure in the control of infections, and most of them are directed to the 
analysis of the sales of ATM in drugstores and decrease in the resistance in the community 
environment18,19. We understand that one of the intuitiveness of the measure was also the 
decrease in the occurrence of microbial resistance in the hospital environment and we 
believe that the results of this study have an innovative character.
This study showed that the restriction to the community use of ATM can reduce hospital 
infections by resistant microorganisms. In a hospital environment, microbial resistance 
is aggravated by different factors, such as fragility of patients’ health conditions and 
proximity to beds, which facilitates the dissemination of cross-Infection5. To understand 
the interference of the community use of ATM in this process favors the implementation 
and improvement of preventive actions, such as the determination of control over the sale 
of ATM normalized by ANVISA through RDC 44/201014.
The results obtained are not restricted to a single hospitalization unit, but comprise different 
clinics of a large teaching hospital, representing a diversified spectrum of health conditions 
that differentiate patients from the susceptibility to MRI.
The criterion used to define infection as of hospital nature was its registration in a period 
equal to or greater than 72 hours of hospital stay, in order to exclude cases of community 
infection. This criterion is defined in Brazil by Ordinance 2,616 of May 12, 199821 and has 
been adopted in different studies23,24. It is not possible to guarantee that some cases detected 
have not been originated in the community.
Table 2. Final model of the association between study phase, age, risk profile and MRI. Belo Horizonte, 
MG, 2010–2011.
Variable
HR (95%CI)
Unadjusted (95%CI) Adjusted*
Study phase
I 1.0 1.0
II 0.54 (0.45–0.65) 0.46 (0.39–0.56)
Age group (years)
Adult (< 60) 1.0 1.0
Older adult (≥ 60) 1.64 (1.37–1.97) 1.56 (1.30–1.88)
Risk profile
Critically ill patients 1.0 1.0
Medical clinic 0.33 (0.27–0.40) 0.29 (0.23–0.35)
Surgical clinic 0.36 (0.28–0.46) 0.34 (0.27–0.44)
HR: hazard ratio; MRI: microbial resistance infection
* adjusted for study phase and age group.
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According to our results, the risk of MRI was lower in the post-implementation phase of 
the restrictive measure, even after adjusting for age. This scenario suggests a reduction 
or greater adequacy of the prescription of ATM in the community, which may have been 
reflected in the cited hospital in the second phase of the study. However, studies indicate 
that, although the implementation of strategies to reduce the consumption of ATM is 
beneficial and can reduce bacterial resistance16, the decrease in consumption may not mean 
a decrease in infections by multidrug-resistant microorganisms, which should also involve 
the rational prescription and the decrease in the consumption of specific classes of ATM16,17. 
Additionally, changes in the behavior of health professionals regarding preventive measures 
of hospital infection may have occurred simultaneously with the reduction in the use of 
ATM, contributing to the reduction in MRI. In the analyzed period, no records or reports of 
restructuring or drastic changes were identified in the routines of the hospital control and 
infection commission in a study that justified the reduction in the internal consumption 
of ATM. Presuming that this assumption is valid, the influence of the immediate impact of 
ANVISA’s resolution on the rationalization of the use of ATM and the adoption of measures 
to prevent hospital infection in Phase II should be considered.
Several studies indicate the abusive use, without indication and in inadequate doses 
as potentiator of the emergence of strains of microorganisms resistant to ATM5,25,26. 
However, it is noteworthy that the actions to control and decrease infections by resistant 
microorganisms are complex and should contemplate not only the restriction of the sale 
of ATM through medical prescription, but other strategies not addressed in RDC 44/2010, 
such as the implementation of educational practices for rational prescription, elaboration 
and implementation of protocols, supervision of prescriptions, hand sanitization campaigns, 
monitoring and health education to patients to guarantee rational use, control of animal 
and environmental use, among others4,17,27. These measures should be carried out not only at 
community level but also in the hospital. This reinforces the need for continuous assessments 
of drug regulatory measures, aiming at the sustainability of MRI reduction. Although 
the reduction in the acquisition of antimicrobials after RDC 44 was not homogeneous 
throughout the country, the region where the study was conducted was the one with the 
largest decrease18.
The limitations of this study include the impossibility of identifying the association between 
the reduction in crop collection in the analyzed times and the reduction in infections or 
colonizations by resistant microorganisms; the short analysis time; the impossibility of 
using the statistical analysis “interrupted time series,” which would be more adequate to 
analyze dependent samples in sequential phases in time; and the use of few control variables. 
Although the period to assess the impact of the restriction on the sale of antimicrobials 
on microorganisms of nosocomial origin may seem short, a systematic review and 
meta-analysis indicate the occurrence of microbial resistance between one and six months 
after the use of ATM28, which corroborates our findings.
Our study identified that the anterior and posterior phases to the restrictive measure 
are independently associated with the reduction of microbial resistance. This is the first 
investigation in Brazil suggesting the influence of restrictive measures on the reduction of 
this type of infection in the hospital environment. Therefore, other studies with the objective 
of monitoring the rates of resistance incidence and the sustainability of the restrictive 
measure must be conducted.
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